593 related articles for article (PubMed ID: 12021250)
21. Effects of Metreleptin in Pediatric Patients With Lipodystrophy.
Brown RJ; Meehan CA; Cochran E; Rother KI; Kleiner DE; Walter M; Gorden P
J Clin Endocrinol Metab; 2017 May; 102(5):1511-1519. PubMed ID: 28324110
[TBL] [Abstract][Full Text] [Related]
22. Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy.
Simha V; Szczepaniak LS; Wagner AJ; DePaoli AM; Garg A
Diabetes Care; 2003 Jan; 26(1):30-5. PubMed ID: 12502655
[TBL] [Abstract][Full Text] [Related]
23. Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience.
Araujo-Vilar D; Sánchez-Iglesias S; Guillín-Amarelle C; Castro A; Lage M; Pazos M; Rial JM; Blasco J; Guillén-Navarro E; Domingo-Jiménez R; del Campo MR; González-Méndez B; Casanueva FF
Endocrine; 2015 May; 49(1):139-47. PubMed ID: 25367549
[TBL] [Abstract][Full Text] [Related]
24. Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy.
Oral EA; Ruiz E; Andewelt A; Sebring N; Wagner AJ; Depaoli AM; Gorden P
J Clin Endocrinol Metab; 2002 Jul; 87(7):3110-7. PubMed ID: 12107209
[TBL] [Abstract][Full Text] [Related]
25. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy.
Shimomura I; Hammer RE; Ikemoto S; Brown MS; Goldstein JL
Nature; 1999 Sep; 401(6748):73-6. PubMed ID: 10485707
[TBL] [Abstract][Full Text] [Related]
26. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature.
Misra A; Garg A
Medicine (Baltimore); 2003 Mar; 82(2):129-46. PubMed ID: 12640189
[TBL] [Abstract][Full Text] [Related]
27. Rapid improvement of hepatic steatosis after initiation of leptin substitution in a leptin-deficient girl.
von Schnurbein J; Heni M; Moss A; Nagel SA; Machann J; Muehleder H; Debatin KM; Farooqi S; Wabitsch M
Horm Res Paediatr; 2013; 79(5):310-7. PubMed ID: 23651953
[TBL] [Abstract][Full Text] [Related]
28. The clinical utility of leptin therapy in metabolic dysfunction.
Park JY; Gavrilova O; Gorden P
Minerva Endocrinol; 2006 Jun; 31(2):125-31. PubMed ID: 16682936
[TBL] [Abstract][Full Text] [Related]
29. Leptin in the treatment of lipodystrophy-associated nonalcoholic fatty liver disease: are we there already?
Machado MV; Cortez-Pinto H
Expert Rev Gastroenterol Hepatol; 2013 Aug; 7(6):513-5. PubMed ID: 23985000
[TBL] [Abstract][Full Text] [Related]
30. A YOUNG ADULT WITH GENERALIZED LIPODYSTROPHY AND DIABETES MELLITUS (CASE REPORT).
Çelo E; Kalari B; Toti F
Georgian Med News; 2018 Apr; (277):27-31. PubMed ID: 29745909
[TBL] [Abstract][Full Text] [Related]
31. Insulin resistance is a sufficient basis for hyperandrogenism in lipodystrophic women with polycystic ovarian syndrome.
Lungu AO; Zadeh ES; Goodling A; Cochran E; Gorden P
J Clin Endocrinol Metab; 2012 Feb; 97(2):563-7. PubMed ID: 22090274
[TBL] [Abstract][Full Text] [Related]
32. Complications of lipodystrophy syndromes.
Akinci G; Celik M; Akinci B
Presse Med; 2021 Nov; 50(3):104085. PubMed ID: 34728268
[TBL] [Abstract][Full Text] [Related]
33. Fat in the liver and insulin resistance.
Yki-Järvinen H
Ann Med; 2005; 37(5):347-56. PubMed ID: 16179270
[TBL] [Abstract][Full Text] [Related]
34. [Lipodystrophy. Mechanisms, clinical presentation, therapy].
Miehle K; Stumvoll M; Fasshauer M
Internist (Berl); 2011 Apr; 52(4):362, 364-6, 368-70 passim. PubMed ID: 21424143
[TBL] [Abstract][Full Text] [Related]
35. Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy.
Moran SA; Patten N; Young JR; Cochran E; Sebring N; Reynolds J; Premkumar A; Depaoli AM; Skarulis MC; Oral EA; Gorden P
Metabolism; 2004 Apr; 53(4):513-9. PubMed ID: 15045701
[TBL] [Abstract][Full Text] [Related]
36. Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy.
Javor ED; Moran SA; Young JR; Cochran EK; DePaoli AM; Oral EA; Turman MA; Blackett PR; Savage DB; O'Rahilly S; Balow JE; Gorden P
J Clin Endocrinol Metab; 2004 Jul; 89(7):3199-207. PubMed ID: 15240593
[TBL] [Abstract][Full Text] [Related]
37. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.
Chan JL; Lutz K; Cochran E; Huang W; Peters Y; Weyer C; Gorden P
Endocr Pract; 2011; 17(6):922-32. PubMed ID: 22068254
[TBL] [Abstract][Full Text] [Related]
38. Leptin in congenital and HIV-associated lipodystrophy.
Tsoukas MA; Farr OM; Mantzoros CS
Metabolism; 2015 Jan; 64(1):47-59. PubMed ID: 25267014
[TBL] [Abstract][Full Text] [Related]
39. Analysis of paradoxical observations on the association between leptin and insulin resistance.
Ceddia RB; Koistinen HA; Zierath JR; Sweeney G
FASEB J; 2002 Aug; 16(10):1163-76. PubMed ID: 12153984
[TBL] [Abstract][Full Text] [Related]
40. Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement.
Polyzos SA; Perakakis N; Mantzoros CS
Metabolism; 2019 Jul; 96():66-82. PubMed ID: 31071311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
